natgillin/translations-raw huggingface dataset:
Uncommon side effects (affecting between 1 in 100 and 1 in 1000 people) • tingling or numbness in hands and feet 
Pogosti neželeni učinki (pojavijo se pri manj kot 1 od 10 bolnikov in več kot 1 od 100 bolnikov) • akutna levkemija
ETOPOPHOS and associated names 100mg Powder for Solution for Infusion ETOPOPHOS and associated names 1000mg Powder for Solution for Infusion [See Annex I - To be completed nationally] 
ETOPOPHOS in povezana imena 100 mg prašek za raztopino za infundiranje ETOPOPHOS in povezana imena 1000 mg prašek za raztopino za infundiranje [Glejte Prilogo I - izpolni država članica.]
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION ETOPOPHOS and associated names 100 mg powder for solution for infusion [See Annex I - To be completed nationally] 
IME ZDRAVILA IN POT(I) UPORABE ETOPOPHOS in povezana imena 100 mg prašek za raztopino za infundiranje [Glejte Prilogo I - izpolni država članica.]
ETOPOPHOS and associated names is indicated in combination with other approved chemotherapeutic agents for the treatment of acute myeloid leukaemia in adult and paediatric patients. 
Zdravilo ETOPOPHOS in povezana imena je, v kombinaciji z drugimi odobrenimi kemoterapevtiki, indicirano za zdravljenje akutne mieloblastne levkemije pri odraslih in pri pediatričnih bolnikih.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION ETOPOPHOS and associated names 1000 mg powder for solution for infusion [See Annex I - To be completed nationally] 
IME ZDRAVILA IN POT(I) UPORABE ETOPOPHOS in povezana imena 1000 mg prašek za raztopino za infundiranje [Glejte Prilogo I - izpolni država članica.]
Sodium citrate 
SEZNAM POMOŽNIH SNOVI natrijev citrat dekstran 40
ETOPOPHOS and associated names is indicated in combination with other approved chemotherapeutic agents for the treatment of non-Hodgkin's lymphoma in adult and paediatric patients. 
Zdravilo ETOPOPHOS in povezana imena je, v kombinaciji z drugimi odobrenimi kemoterapevtiki, indicirano za zdravljenje ne-Hodgkinovega limfoma pri odraslih in pri pediatričnih bolnikih.
Administration and Dosage 
Dajanje in odmerjanje
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial Label (1000 mg) 
Nalepka na viali (1000 mg)
ETOPOPHOS and associated names is indicated for first line and second line therapy in combination with other approved chemotherapeutic agents for the treatment of high risk gestational trophoblastic neoplasia in adults. 
Zdravilo ETOPOPHOS in povezana imena je, v kombinaciji z drugimi odobrenimi kemoterapevtiki, indicirano za prvo in drugo linijo zdravljenja visokotvegane gestacijske trofoblastne neoplazije.
ETOPOPHOS and associated names is indicated in combination with other approved chemotherapeutic agents for the treatment of Hodgkin's lymphoma in adult and paediatric patients. 
Zdravilo ETOPOPHOS in povezana imena je, v kombinaciji z drugimi odobrenimi kemoterapevtiki, indicirano za zdravljenje Hodgkinovega limfoma pri odraslih in pri pediatričnih bolnikih.
What ETOPOPHOS and associated names is and what it is used for 
Kaj je zdravilo ETOPOPHOS in povezana imena in za kaj ga uporabljamo To zdravilo se imenuje ETOPOPHOS in povezana imena.
ETOPOPHOS and associated names is indicated in combination with other approved chemotherapeutic agents for the treatment of non-epithelial ovarian cancer in adults. 
Zdravilo ETOPOPHOS in povezana imena je, v kombinaciji z drugimi odobrenimi kemoterapevtiki, indicirano za zdravljenje neepitelijskega raka jajčnikov pri odraslih.
Nadirs tend to occur earlier with intravenous administration compared to oral administration. 
Najnižje vrednosti se običajno pojavijo prej v primeru intravenske kot v primeru peroralne uporabe.
The usual dose, based on etoposide, is 50 to100mg/m2 body surface area, daily for 5 days in a row or 100 to 120 mg/ m2 body surface area on days 1, 3 and 5. 
Običajni odmerek, ki temelji na etopozidu, je 50 do 100 mg/m2 telesne površine dnevno, 5 dni zapored ali 100 do 120 mg/m2 telesne površine 1., 3. in 5. dan. Cikel zdravljenja se nato lahko ponovi glede na rezultate krvnih preiskav, vendar ne prej kot 21 dni po zaključku prvega cikla zdravljenja.
Date 
DRUGI PODATKI
Reports of fever and infection were also very common in patients with neutropenia treated with etoposide phosphate. 
Pri bolnikih z nevtropenijo, ki so se zdravili z etopozid fosfatom, so zelo pogosto poročali o zvišani telesni temperaturi in okužbah.
ETOPOPHOS and associated names contains 
ETOPOPHOS in povezana imena.
• constipation 
• krvavitev
- if you are taking any drugs with a similar mechanism of action as ETOPOPHOS and associated names. 
- Če jemljete katera koli zdravila s podobnim načinom delovanja, kot ga ima zdravilo
STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains etoposide 100 mg (as phosphate) Each vial contains etoposide 1000 mg (as phosphate) 
NAVEDBA ENE ALI VEČ UČINKOVIN Ena viala vsebuje 100 mg etopozida (v obliki fosfata).
Each vial contains etoposide phosphate equivalent to etoposide 100 mg or 1000 mg as the active ingredient. 
Ena viala vsebuje 100 mg ali 1000 mg etopozida v obliki etopozid fosfata.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial Label (100 mg) 
Nalepka na viali (100 mg)
How to store ETOPOPHOS and associated names 
Kaj vsebuje zdravilo ETOPOPHOS in povezana imena
Fatal myelosuppression has been reported following etoposide phosphate administration. 
Po dajanju etopozid fosfata so poročali o smrti zaradi mielosupresije.
Myelosuppression (see section 4.4) with fatal outcome has been reported following administration of etoposide phosphate. 
Po uporabi etopozid fosfata so poročali o smrti zaradi mielosupresije (glejte poglavje 4.4).
December 2025 
decembra 2025
June 2020 
junija 2020
Aseptic technique must be used. 
Uporabiti je treba aseptično tehniko.
Adults >21 years 
Odrasli, stari > 21 let
t1/2 (day) 
t1/2 (dni)
Ask your doctor for advice on the best contraceptive method that you can use. 
Posvetujte se z zdravnikom o najboljši kontracepcijski metodi, ki jo lahko uporabite.
There are no data available for elderly patients. 
Podatki za starejše bolnike niso na voljo.
8 months. 
8 mesecev
It should only be given in a hospital setting where appropriate resuscitation equipment is available. 
Zdravilo se lahko daje samo v bolnišnici, kjer je na voljo primerna oprema za oživljanje.
Your physician will decide whether your disease requires treatment. 
Zdravnik bo presodil, ali je treba vašo bolezen zdraviti.
Therapeutic efficacy was defined as a clinical improvement which did not meet the criteria for other beneficial outcomes. 
Terapevtska učinkovitost je bila opredeljena kot klinično izboljšanje, ki ne izpolnjuje meril za druge ugodne izide.
In very rare cases, mild tremor in the fingers has been described. 
V zelo redkih primerih je bil opisan blag tremor v prstih.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 14 January 2016 
Datum prve odobritve: 14. januar 2016
Alteration of liver parameters is common. 
Spremembe jetrnih parametrov so pogoste.
Medical equipment to treat allergic reactions will be available nearby. 
V bližini bo na voljo medicinska oprema za zdravljenje alergijskih reakcij.
Patients should be monitored for changes in liver function parameters. 
Bolnike moramo spremljati za spremembe v parametrih jetrne funkcije.
Not known: Pyrexia 
Neznana: pireksija
Staff should be trained in how to handle and transfer the medicinal product (pregnant staff should be excluded from working with this medicinal product). 
Osebje je treba usposobiti za ravnanje z zdravilom in njegov prenos (nosečnice s tem zdravilom ne smejo delati).
If higher volume is given, the dose should be divided and given at several injection sites. 
Če dajemo večji volumen, moramo odmerek razdeliti in ga dati na več mestih injiciranja.
All items for administration or cleaning, including gloves, should be placed in high-risk waste disposal bags for high-temperature incineration. 
Vse predmete, namenjene dajanju ali čiščenju, vključno z rokavicami, je treba odložiti v vreče za odpadke z visokim tveganjem, namenjene sežiganju pri visokih temperaturah.
In general, incidence and type of adverse reactions Grade 3 and 4 were similar between the two treatment groups. 
Na splošno sta bili pojavnost in vrsta neželenih učinkov 3. in 4. stopnje podobni v obeh skupinah zdravljenja.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. 
Nosečnost in dojenje Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden uporabite to zdravilo.
The proportion of patients with this level of depletion was similar between the 2 study arms during all 3 phases of treatment at the protocol-specified time points. 
Delež bolnikov s takšnim upadom je bil podoben v obeh skupinah študije v vseh 3 fazah zdravljenja ob časovnih točkah, opredeljenih v protokolu.
Tell your doctor if any of these conditions apply to you. 
Obvestite zdravnika, če kaj od navedenega velja za vas.
ALL is a white blood cell cancer type in which certain immature white cells (named lymphoblasts) start growing out of control thus preventing the production of functional blood cells. 
ALL je vrsta raka belih krvnih celic, pri katerem se začne število določenih nezrelih belih krvnih celic (imenovanih limfoblasti) nenadzorovano povečevati in s tem prepreči nastajanje delujočih krvnih celic.
This can promote the tendency to bleeding and/or thrombosis. 
To lahko spodbuja nagnjenost h krvavitvam in/ali k trombozi.
During Oncaspar administration you will be closely watched for an hour after the start of treatment for any signs of serious allergic reactions. 
Med dajanjem zdravila Oncaspar vas bodo eno uro po začetku zdravljenja natančno spremljali glede morebitnih znakov resne alergijske reakcije.
This leaflet was last revised in 
Navodilo je bilo nazadnje revidirane dne
You should not use Oncaspar if you are pregnant because its effects during pregnancy have not been studied. 
Zdravila Oncaspar ne smete uporabljati, če ste noseči, ker njegovih učinkov med nosečnostjo niso preučevali.
Normal cells can make asparagine for themselves, while some cancer cells cannot. 
Normalne celice lahko same proizvajajo asparagin, nekatere rakave celice pa ga ne morejo.
Men must also use effective contraception while they or their partners are treated with Oncaspar. 
Tudi moški morajo uporabljati učinkovito kontracepcijo, medtem ko se sami ali njihove partnerice zdravijo z zdravilom Oncaspar.
If symptoms of hyperammonaemia exist, ammonia levels should be monitored closely. 
Če se pojavijo simptomi hiperamoniemije, moramo ravni amoniaka natančno spremljati.
- vincristine, another cancer medicine. 
- vinkristin (drugo zdravilo za raka).
In case of overdose, patients must be carefully monitored for signs and symptoms of adverse reactions, and appropriately managed with symptomatic and supportive treatment. 
V primeru prevelikega odmerjanja moramo bolnike skrbno spremljati glede znakov in simptomov neželenih učinkov in jih ustrezno obravnavati s simptomatskim in podpornim zdravljenjem.
Cmax (mU/mL)* Tmax (hr)* 
Cmax (me./ml)* Tmax (h)*
Warning: special handling instructions (see package leaflet) 
Opozorilo: posebna navodila za ravnanje (glejte navodilo za uporabo).
Elderly There are limited data available for patients older than 65 years. 
Starejši bolniki Podatkov pri bolnikih, starejših od 65 let, je malo.
In severe cases, encephalopathy can develop with or without hepatic impairment, especially in older adults, which can be life-threatening or fatal. 
V hudih primerih se lahko pojavi encefalopatija z jetrno okvaro ali brez nje, zlasti pri starejših bolnikih, ki je lahko življenjsko nevarna ali smrtna.
The controlled studies were not designed to formally evaluate the pharmacokinetics of Oncaspar in specific populations. 
Nadzorovane študije niso bile načrtovane za formalno ocenjevanje farmakokinetike zdravila Oncaspar v specifičnih populacijah.
Investigations of the effect on fertility and peri- and postnatal development were not conducted. 
Raziskave učinkov na plodnost in peri-/postnatalni razvoj niso bile opravljene.
Therefore, vincristine should be given at least 12 hours prior to administration of Oncaspar in order to minimise toxicity. 
Zato je treba vinkristin dati vsaj 12 ur pred dajanjem zdravila Oncaspar, da se toksičnost zmanjša na najmanjšo možno mero.
Due to the risk of hyperbilirubinaemia, it is recommended to monitor bilirubin levels at baseline and prior to each dose. 
Zaradi tveganja za hiperbilirubinemijo je priporočljivo spremljati ravni bilirubina na začetku in pred vsakim odmerkom.
If these substances are given subsequently, the effect of pegaspargase can be weakened antagonistically. 
Če ti učinkovini damo naknadno, je lahko učinek pegaspargaze antagonistično oslabljen.
In the unlikely event of accidental overdose, you will be monitored carefully by medical staff and treated appropriately. 
V malo verjetnem primeru nenamernega prevelikega odmerjanja vas bo zdravstveno osebje skrbno spremljalo in ustrezno zdravilo.
Severe hepatic impairment (bilirubin >3 times upper limit of normal [ULN]; transaminases >10 times ULN). 
Huda jetrna okvara (bilirubin > 3-kratna zgornja meja normalnih vrednosti [ULN]; transaminaze > 10-kratna ULN).
Reduced splenic weight might be a sign of potential immunosuppressant effect of the treatment. 
Zmanjšana masa vranice je lahko znak potencialnega imunosupresivnega učinka zdravljenja.
Oncaspar is used together with other medicines. 
Zdravilo Oncaspar se uporablja skupaj z drugimi zdravili.
Oncaspar contains pegaspargase, which is an enzyme (asparaginase) that breaks down asparagine, an important building block of proteins without which cells cannot survive. 
Zdravilo Oncaspar vsebuje pegaspargazo, encim (asparaginazo), ki razgrajuje asparagin, pomemben gradnik beljakovin, brez katerih celice ne morejo preživeti.
Based on its pharmacological properties, any risk to the breast-fed newborns/infants cannot be excluded. 
Zaradi farmakoloških lastnosti zdravila tveganja za dojenega novorojenca/otroka ne moremo izključiti.
- medicines which require cell division for their effect, for example, methotrexate (a medicine used for cancer as well as arthritis treatment) may have a decrease in its effect. 
- zdravila, ki za svoje delovanje zahtevajo celično delitev, npr. metotreksat (zdravilo, ki se uporablja za zdravljenje raka in artritisa), imajo lahko manjši učinek;
Grade 3 or higher febrile neutropenia was 15.4%. 
Febrilne nevtropenije 3. stopnje ali višje je bilo 15,4 %.
When there is a marked decrease in fibrinogen or antithrombin III (ATIII) deficiency, consider appropriate replacement therapy. 
V primeru izrazitega znižanja ravni fibrinogena ali pomanjkanja antitrombina III (ATIII) moramo razmisliti o ustreznem nadomestnem zdravljenju.
AUC0-t (mUday/mL)* AUC0-∞ (mUday/mL) 
AUC0-t (me.dan/ml)* AUC0-∞ (me.dan/ml)
Treatment may be monitored based on the trough serum asparaginase activity measured before the next administration of pegaspargase. 
Zdravljenje se lahko spremlja na podlagi aktivnosti serumske asparaginaze, izmerjene pred naslednjim dajanjem pegaspargaze.
Neutralising antibodies reducing clinical efficacy were also recorded. 
Zaznali so tudi nevtralizirajoča protitelesa, ki so zmanjšala klinično učinkovitost.
The protocol-specified goal was achievement of asparagine depletion to a serum concentration of ≤1 µM. 
Cilj, opredeljen v protokolu, je bil doseči upad ravni asparagina na serumsko koncentracijo ≤ 1 µM.
Arithmetic Mean (SD) 
Aritmetična sredina (SD)
Days After First Dose of L-Asparaginase 
Dni po prvem odmerku L-asparaginaze
The decrease in serum proteins caused by pegaspargase can increase the toxicity of other medicinal products that are protein bound. 
Znižanje ravni serumskih beljakovin, ki jih povzroči pegaspargaza, lahko poveča toksičnost drugih zdravil, ki se vežejo na beljakovine.
A pilot study was conducted for newly diagnosed patients from 1 to <31 years of age with high risk B-precursor ALL (Study AALL07P4). 
Opravljena je bila pilotna študija pri bolnikih, starih od 1 do < 31 let, z novo diagnozo ALL B-prekurzorjev z visokim tveganjem (študija AALL07P4).
It is not known whether pegaspargase is excreted into the breast milk. 
Ni znano, ali se pegaspargaza izloča v materino mleko.
For storage conditions of the reconstituted and diluted medicinal product, see section 6.3. 
Za pogoje shranjevanja rekonstituiranega in razredčenega zdravila glejte poglavje 6.3.
Treatment was administered during Induction (Day 7), and then every 2 weeks for a total of 30 weeks post-Induction therapy. 
Zdravljenje so dali med indukcijo (7. dan) in nato vsake 2 tedna skupno 30 tednov po indukcijskem zdravljenju.
This medicine can lead to fluctuations in clotting factors and may increase the risk of bleeding and/or clotting. 
To zdravilo lahko povzroči nihanja ravni faktorjev strjevanja krvi in poveča tveganje za krvavitve in/ali strjevanje krvi.
The decrease in the number of circulating lymphoblasts is often quite marked, and normal or too low leukocyte counts are often seen in the first days after the start of therapy. 
Zmanjšanje števila limfoblastov v obtoku je zelo izrazito in v prvih dneh po začetku zdravljenja je pogosto opaziti normalno ali prenizko število levkocitov.
Therefore, use of Oncaspar could increase the risk of infections. 
Zato lahko uporaba zdravila Oncaspar poveča tveganje za okužbe.
A rise in serum urea occurs regularly, is dose-independent and nearly always a sign of pre-renal metabolic imbalance. 
Zvišanje ravni sečnine v serumu se pojavlja redno, je neodvisno od odmerka in skoraj vedno znak predledvičnega presnovnega neravnovesja.
The vial should be gently swirled until the powder is reconstituted. 
Vialo je treba narahlo vrteti, dokler se prašek ne raztopi.
Not known: Confusional state 
Neznana: stanje zmedenosti
If not used immediately, in-use storage times and conditions are the responsibility of the user. 
Če se zdravilo ne uporabi takoj, je za čase shranjevanja in pogoje pred uporabo odgovoren uporabnik.
In such cases, a switch to a different asparaginase preparation should be considered. 
V takšnih primerih je treba razmisliti o prehodu na drugo zdravilo z asparaginazo.
Asparagine concentration fell to <3 µM when asparaginase activity was >0.1 U/mL. 
Raven asparagina je upadla za < 3 µM, če je bila aktivnost asparaginaze > 0,1 e./ml.
For instructions on reconstitution and dilution of this medicinal product before administration, see section 6.6. 
Za navodila glede rekonstitucije in redčenja tega zdravila pred dajanjem glejte poglavje 6.6.
There is no specific pharmacological treatment for the overdose. 
Specifičnega farmakološkega zdravljenja za preveliko odmerjanje ni.
Simultaneous vaccination with live vaccines may increase the risk of severe infections attributable to the immunosuppressive activity of pegaspargase, the presence of the underlying disease and combination chemotherapy (see section 4.4). 
Sočasno cepljenje z živimi cepivi lahko poveča tveganje za hude okužbe, kar je posledica imunosupresivne aktivnosti pegaspargaze, prisotnosti osnovne bolezni in kombinirane kemoterapije (glejte poglavje 4.4).
Common: Hypoxia 
Pogosti: hipoksija
It should be explained to patients that Oncaspar should not be used at the same time as other medicines associated with an increased risk of bleeding (see section 2 “Other medicines and Oncaspar”). 
Bolnikom moramo pojasniti, da se zdravilo Oncaspar ne sme uporabljati sočasno z drugimi zdravili, povezanimi s povečanim tveganjem za krvavitev (glejte poglavje 2 Druga zdravila in zdravilo Oncaspar).
MARKETING AUTHORISATION NUMBER(S) EU/1/15/1070/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/15/1070/001
Table 2: Event-free survival rate at 3, 5 and 7 years (Study CCG-1962) 
Preglednica 2: Preživetje brez dogodkov po 3, 5 in 7 letih (študija CCG-1962)
Asparaginase facilitates the rapid conversion of asparagine and glutamine to aspartic acid and glutamic acid, with ammonia as the shared by-product of both reactions (see section 5.1). 
Asparaginaza pospešuje hitro pretvorbo asparagina in glutamina v asparaginsko kislino in glutaminsko kislino, stranski produkt obeh reakcij pa je amoniak (glejte poglavje 5.1).
In Study CCG-1962, the most common adverse reactions were infections, including two life-threatening infections (1 patient in each arm). 
V študiji CCG-1962 so bili najpogostejši neželeni učinki okužbe, vključno z dvema življenjsko nevarnima okužbama (po 1 bolnik v vsaki skupini).
The powder must be reconstituted with 5.2 ml water for injections prior to administration (see section 4.2). 
Prašek je treba pred dajanjem rekonstituirati s 5,2 ml vode za injekcije (glejte poglavje 4.2).
Both diabetic ketoacidosis and hyperosmolar hyperglycaemia have been described, which generally respond to administration of insulin. 
Opisani sta bili diabetična ketoacidoza in hiperosmolarna hiperglikemija, ki se običajno odzoveta na uporabo insulina.
For intramuscular injection, the volume should not exceed 2 ml in children and adolescents and 3 ml in adults. 
Pri intramuskularni injekciji volumen ne sme presegati 2 ml pri otrocih in mladostnikih ter 3 ml pri odraslih.
Since an indirect interaction between the oral contraceptives and pegaspargase cannot be ruled out, the use of oral contraception is not considered an acceptable method of contraception (see sections 4.5 and 4.6). 
Ker posredne interakcije med peroralnimi kontraceptivi in pegaspargazo ni mogoče izključiti, uporabe peroralnih kontraceptivov ne štejemo za sprejemljivo metodo kontracepcije (glejte poglavji 4.5 in 4.6).
When glucocorticoids (e.g., prednisone) and pegaspargase are given at the same time, alterations in coagulation parameters (e.g., fall in fibrinogen and antithrombin III deficiency, ATIII) can be more pronounced. 
Pri sočasni uporabi glukokortikoidov (npr. prednizona) in pegaspargaze lahko spremembe v koagulacijskih parametrih (npr. padec ravni fibrinogena in pomanjkanje antitrombina III, ATIII) postanejo bolj izrazite.
The medicine is given as a solution by injection into a muscle or, if more suitable, into a vein. 
Zdravilo se daje kot raztopina z injiciranjem v mišico ali v veno, če je slednje primernejše.
Adverse reactions and their frequencies are reported in Table 1. 
Neželeni učinki in njihove pogostnosti so navedeni v Preglednici 1.
In rare cases, a reversible posterior leukoencephalopathy syndrome (RPLS) may occur. 
V redkih primerih se lahko pojavi sindrom reverzibilne posteriorne levkoencefalopatije (RPLS).
Overall, from five studies analysed based on 65 ALL patients exposed to Oncaspar using the highest therapeutic response during the entire study, complete remission was observed in 30 patients (46%), partial remission in 7 patients (11%) and haematological improvement in 1 patient (2%). 
Skupno so v 5 analiziranih študijah s 65 bolniki z ALL, ki so bili izpostavljeni zdravilu Oncaspar, na podlagi največjega terapevtskega odziva v celotni študiji ugotovili popolno remisijo pri 30 bolnikih (46 %), delno remisijo pri 7 bolnikih (11 %) in hematološko izboljšanje pri 1 bolniku (2 %).
Although they have not been specifically associated with the use of pegaspargase, they may occur with the use of Oncaspar: 
Čeprav niso bili konkretno povezani z uporabo pegaspargaze, se lahko pojavijo med uporabo zdravila Oncaspar:
The patterns of serum asparagine depletion in the 2 delayed intensification phases are similar to the pattern of serum asparagine depletion in the induction phase. 
Vzorci upada serumske ravni asparagina v obeh fazah pozne intenzifikacije so podobni vzorcem upada serumske ravni asparagina v indukcijski fazi.
The immediate cell death of leukaemic cells in vivo, measured by rhodamine fluorescence, was the same for all three L-asparaginase preparations. 
Takojšnja celična smrt levkemičnih celic in vivo, izmerjena s fluorescenco rodamina, je bila enaka pri vseh treh zdravilih z L-asparaginazo.
The mean half-life after absorption from the injection site was 1.7 days and the elimination half-life was 5.5 days. 
Povprečna razpolovna doba po absorpciji z mesta injiciranja je bila 1,7 dni, razpolovna doba izločanja pa 5,5 dni.